Cardiff Oncology, Inc. Share Price & Technical Analysis
CRDF · $1.94 (+8.99%)
Healthcare / Biotechnology
$1.94
+8.99%
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in …
Price chart
Seasonality
May has 1 positive and 2 negative years (last 5 years shown)
0% return in May, -6% avg return in past 3 year May month.
-46% return in 2026, 62% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -36% | 6% | -16% | 0% | 0% | – | – | – | – | – | – | – | -46% |
| 25 | -9% | 11% | -28% | -13% | 21% | -9% | -25% | -16% | 0% | 15% | 0% | 22% | -31% |
| 24 | 7% | 13% | 165% | -19% | -27% | -31% | 5% | 0% | 17% | 15% | -16% | 65% | 193% |
| 23 | 29% | -6% | -6% | 0% | -11% | -6% | 20% | 0% | -26% | -15% | 20% | 25% | 23% |
| 22 | -44% | -21% | -7% | -48% | 0% | 57% | 0% | 23% | -44% | 0% | 0% | -12% | -97% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$111.44M
P/E ratio
—
52W high
$4.56
52W low
$1.48
Volume
18,28,343
Beta
1.36
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Cardiff Oncology, Inc. share price today?
- Cardiff Oncology, Inc. (CRDF) last traded around $1.94 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CRDF have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CRDF. Download the app for real-time alerts.
- How can I analyze Cardiff Oncology, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.